Humoral immune response induced by an engineered cell-based neuroblastoma vaccine with or without CD25 blockade

Acta Biochimica et Biophysica Sinica

Volumn 43, Issue 2, 2011, Pages 124-132

  Zheng, Jin ^a   Orentas, Rimas ^b   Yan, Xiaofei ^a   Liu, Hongli ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Costimulator; Humoral immunity; Neuroblastoma; Treg blockade; Tumor bearing

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2 RECEPTOR ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL; ARTICLE; BLOOD; DRUG ANTAGONISM; GENE LIBRARY; HUMORAL IMMUNITY; IMMUNOLOGY; MOUSE; NEUROBLASTOMA; REGULATORY T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; GENE LIBRARY; IMMUNITY, HUMORAL; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; NEUROBLASTOMA; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 79551548526     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmq123     Document Type: Article

References (53)

1. Izbicki T, Mazur J and Izbicka E. Epidemiology and etiology of neuroblastoma: an overview. Anticancer Res 2003, 23: 755-760.
2. Evans AE and Hummeler K. The significance of primitive cells in marrow aspirates of children with neuroblastoma. Cancer 1973, 32: 906-912.
3. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK and Swift P, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. New Engl J Med 1999, 341: 1165-1173.
4. Rousseau RF and Brenner MK. Vaccine therapies for pediatric malignancies. Cancer J 2005, 11: 331-339.
5. Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z and Smith SC, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003, 101: 1718-1726.
6. Johnson BD, Yan X, Schauer DW and Orentas RJ. Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cell Immunol 2003, 222: 15-26.
7. Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X and Orentas RJ. Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. J Immunother 2005, 28: 449-460.
8. Yan XC, Johnson BD and Orentas RJ. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology 2004, 112: 105-116.
9. Cantor H, Shen FW and Boyse EA. Separation of helper T cells from suppressor T cells expressing different Ly components. II. Activation by antigen: after immunization, antigen-specific suppressor and helper activities are mediated by distinct T-cell subclasses. J Exp Med 1976, 143: 1391-1400.
10. Gershon RK and Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970, 18: 723-737.
11. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M and Huniyasu Y, et al. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182: 18-23.
12. Fanning LJ, Connor AM and Wu GE. Development of the immunoglobulin repertoire. Clin Immunol Immunopathol 1996, 79: 1-14.
13. Janeway CA, Travers P, Walport M and Shlomchik MT. Immunobiology, 6th edn. New York, Garland Pub. Inc., 2005, 387-397.
14. Neuberger MS and Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol 1981, 11: 1012-1016.
15. Gessner JE, Heiken H, Tamm A and Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998, 76: 231-248.
16. Unkeless JC and Eisen HN. Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages. J Exp Med 1975, 142: 1520-1533.
17. Kipps TJ, Parham P, Punt J and Herzenberg LA. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 1985, 161: 1-17.
18. Takai T, Li M, Sylvestre D, Clynes R and Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994, 76: 519-529.
19. Huber VC, Lynch JM, Bucher DJ, Le J and Metzger DW. Fc receptormediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001, 166: 7381-7388.
20. Nimmerjahn F, Bruhns P, Horiuchi K and Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005, 23: 41-51.
21. Nimmerjahn F and Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005, 310: 1510-1512.
22. Zheng J, Jing WQ and Orentas RJ. Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade. Acta Biochim Biophys Sin 2009, 41: 980-990.
23. Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO and Jager D, et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun 2001, 1: 2-4.
24. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S and Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997, 15: 3363-3367.
25. Crawford LV, Pim DC and Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30: 403-408.
26. Willsher PC, Pinder SE, Robertson L, Nicholson RI, Ellis IO, Bell JA and Blamey RW. The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 1996, 16: 927-930.
27. Anderson KS and LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005, 4: 1123-1133.
28. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003, 21: 37-38.
29. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF and Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989, 143: 2714-2722.
30. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K and Ito D, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995, 154: 97-105.
31. Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A and Linsley PS. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28. J Biol Chem 1995, 270: 21181-21187.
32. Kwon BS and Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 1989, 86: 1963-1967.
33. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO and Kwon BS. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1J. Immunol 2002, 169: 4882-4888.
34. Stärck L, Scholz C, Dö rken B and Daniel PT. Costimulation by CD137/ 4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol 2005, 35: 1257-1266.
35. Bertram EM, Dawicki W, Sedgmen B, Bramson JL, Lynch DH and Watts TH. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol 2004, 172: 981-988.
36. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE and Mittler RS. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3: 682-685.
37. Golgher D, Jones E, Powrie F, Elliot T and Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002, 32: 3267-3275.
38. Johnson BD, Jing W and Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother 2007, 30: 203-214.
39. Coutelier JP, van der Logt JT, Heessen FW, Vink A and van Snick J. Virally induced modulation of murine IgG antibody subclasses. J Exp Med 1988, 168: 2373-2378.
40. Gerhard W, Mozdzanowska K, Furchner M, Washko G and Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 1997, 159: 95-103.
41. Yan W, Rajkovic A, Viveiros MM, Burns KH and Eppig JJ. Identification of Gasz, an evolutionarily conserved gene expressed exclusively in germ cells and encoding a protein with four ankyrin repeats, a sterile-alpha motif, and a basic leucine zipper. Mol Endocrinol 2002, 16: 1168-1184.
42. Yan W, Ma L, Zilinski CA and Matzuk MM. Identification and characterization of evolutionarily conserved pufferfish, zebrafish, and frog orthologs of GASZ. Biol Reprod 2004, 70: 1619-1625.
43. Jones TA, Barker HM, da Cruz e Silva EF, Mayer-Jaekel RE, Hemmings BA, Spurr NK and Sheer D, et al. Localization of the genes encoding the catalytic subunits of protein phosphatase 2A to human chromosome bands 5q23-q31 and 8p12-p11.2, respectively. Cytogenet Cell Genet 1993, 63: 35-41.
44. Fritzler MJ, Lung CC, Hamel JC, Griffith KJ and Chan EK. Molecular characterization of golgin-245, a novel Golgi complex protein containing a granin signature. J Biol Chem 1995, 270: 31262-31268.
45. Nicoloso M, Caizergues-Ferrer M, Michot B, Azum MC and Bachellerie JP. U20, a novel small nucleolar RNA, is encoded in an intron of the nucleolin gene in mammals. Mol Cell Biol 1994, 14: 5766-5776.
46. Filie JD, Buckler CE and Kozak CA. Genetic mapping of the mouse ferritin light chain gene and 11 pseudogenes on 11 mouse chromosomes. Mamm Genome 1998, 9: 111-113.
47. Wei J, Dlouhy SR, Hara A, Ghetti B and Hodes ME. Cloning a cDNA for carbonyl reductase (Cbr) from mouse cerebellum: murine genes that express Cbr map to chromosomes 16 and 11. Genomics 1996, 34: 147-148.
48. von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A and Grosveld G. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992, 12: 1687-1697.
49. Haft CR, de la Luz Sierra M, Barr VA, Haft DH and Taylor SI. Identification of a family of sorting nexin molecules and characterization of their association with receptors. Mol Cell Biol 1998, 18: 7278-7287.
50. Kaneko-Ishino T, Kuroiwa Y, Miyoshi N, Kohda T, Suzuki R, Yokoyama M and Viville S, et al. Peg1/Mest imprinted gene on chromosome 6 identified by cDNA subtraction hybridization. Nature Genet 1995, 11: 52-59.
51. Howard L, Nelson KK, Maciewicz RA and Blobel CP. Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domaincontaining proteins, endophilin I and SH3PX1. J Biol Chem 1999, 274: 31693-31699.
52. Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S and Papageorgiou T, et al. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 2003, 63: 5308-5319.
53. Bell AW, Ward MA, Blackstock WP, Freeman HNM, Choudhary JS, Lewis AP and Chotai D, et al. Proteomics characterization of abundant Golgi membrane proteins. J Biol Chem 2001, 276: 5152-5165.